Search research articles
Contact Us
Filters
Showing results (281-290 of 286) with videos related to
Page
of 29
Sort By:
You have reached the last page of results.
This site can display upto 286 results.
The Lancet. Oncology
|
November 1, 2025
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial
Timothy F Cloughesy, Martin J van den Bent, Mehdi Touat, et al.
Neuro-Oncology
|
December 28, 2020
Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank
Pavlina Chuntova, Frances Chow, Payal B Watchmaker, et al.
Nature Medicine
|
February 12, 2019
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
Timothy F Cloughesy, Aaron Y Mochizuki, Joey R Orpilla, et al.
The Lancet. Oncology
|
August 4, 2023
National Cancer Institute Collaborative Workshop on Shaping the Landscape of Brain Metastases Research: challenges and recommended priorities
Michelle M Kim, Minesh P Mehta, DeeDee K Smart, et al.
Cancer Discovery
|
August 16, 2023
Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Sriram Venneti, Abed Rahman Kawakibi, Sunjong Ji, et al.
Nature Communications
|
December 5, 2022
Federated learning enables big data for rare cancer boundary detection
Sarthak Pati, Ujjwal Baid, Brandon Edwards, et al.
Page
of 29
Search research articles
Search
Showing results (281-290 of 286) with videos related to
Sort By:
Page
of 29
You have reached the last page of results.
This site can display upto 286 results.
The Lancet. Oncology
|
November 1, 2025
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial
Timothy F Cloughesy, Martin J van den Bent, Mehdi Touat, et al.
Neuro-Oncology
|
December 28, 2020
Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank
Pavlina Chuntova, Frances Chow, Payal B Watchmaker, et al.
Nature Medicine
|
February 12, 2019
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
Timothy F Cloughesy, Aaron Y Mochizuki, Joey R Orpilla, et al.
The Lancet. Oncology
|
August 4, 2023
National Cancer Institute Collaborative Workshop on Shaping the Landscape of Brain Metastases Research: challenges and recommended priorities
Michelle M Kim, Minesh P Mehta, DeeDee K Smart, et al.
Cancer Discovery
|
August 16, 2023
Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Sriram Venneti, Abed Rahman Kawakibi, Sunjong Ji, et al.
Nature Communications
|
December 5, 2022
Federated learning enables big data for rare cancer boundary detection
Sarthak Pati, Ujjwal Baid, Brandon Edwards, et al.
Page
of 29